What is a normal hs-CRP level for a man over 40?

The American Heart Association and Centers for Disease Control classify hs-CRP under 1.0 milligrams per litre as low risk, 1.0 to 3.0 as average risk and above 3.0 as high risk. Most men over 40 in population surveys land somewhere in the 1 to 2 range. A value above 10 milligrams per litre falls outside this scheme entirely and generally reflects an acute process such as infection or injury rather than a chronic baseline.

What is the difference between CRP and hs-CRP?

They measure the same protein using assays with different sensitivity. A standard CRP test is designed to detect the large elevations seen in infection and inflammatory disease and loses resolution below roughly 3 to 5 milligrams per litre. The high sensitivity assay reads reliably down to about 0.1 to 0.3 milligrams per litre, which is the range where the cardiovascular risk signal in apparently healthy people is found. Ordering a standard CRP for risk assessment produces a number that cannot answer the question.

Why does my hs-CRP keep changing between tests?

Within-person variability in hs-CRP is high, and a single value can move between risk bands on repeat testing without any real change in a man's health. Recent hard exercise, a minor infection, a dental procedure, a vaccination and poor sleep all raise it temporarily. This is why the AHA and CDC statement recommends two measurements taken about two weeks apart and averaged, and why serial values under matched conditions are more informative than any single draw.

How do you lower hs-CRP naturally?

Fat loss is the most consistent lever, with pooled analyses estimating roughly 0.13 milligrams per litre of reduction per kilogram of weight lost. Stopping smoking, treating periodontal disease and treating obstructive sleep apnea all lower inflammatory markers in studies, and each of those is frequently the hidden source in a man who cannot explain his value. Exercise helps, though meta-analyses suggest most of its effect on C-reactive protein runs through the fat loss it produces rather than through training itself.

Does high hs-CRP mean I will have a heart attack?

No. hs-CRP is a probabilistic risk marker measured across populations and it does not predict an event in any individual man. An elevated value indicates that a man carries more risk than another man with identical cholesterol and a low value, which is useful for deciding how aggressively to manage the rest of his risk profile. It is one input alongside apoB, blood pressure, glucose, smoking status and family history, and interpreting it in isolation is a mistake.

Is there a link between hs-CRP and low testosterone?

Observational studies in middle aged and older men consistently find that lower total testosterone tends to accompany higher C-reactive protein and interleukin-6. The direction of causation is unresolved, and visceral adiposity is a plausible shared cause since it both lowers testosterone through increased aromatase activity and raises inflammatory signalling. Interventional data on whether testosterone therapy lowers C-reactive protein is mixed, and no evidence supports using hormone therapy to manage an inflammatory marker.

Do supplements like curcumin or fish oil lower hs-CRP?

Marine omega-3 intake is associated with lower inflammatory markers, and curcumin has reduced C-reactive protein in some small trials, but the effect sizes in both cases are modest next to what fat loss produces. A man carrying substantial visceral fat or an untreated sleep apnea is working on a small contributor while a large one goes unaddressed. Supplements are also poorly standardised for absorption, which makes trial results difficult to map onto a specific product on a shelf.

Should I ask my doctor for an hs-CRP test?

It is a reasonable request for a man over 40 who is already having bloodwork drawn and whose cardiovascular risk is not clearly high or clearly low, since the test costs little and its main use is reclassifying men in that ambiguous middle. It is less useful for a man at clearly high risk who is already being managed, or for a man who has no intention of acting on the result. Any decision about what to do with the number belongs with the physician ordering it.

testosterone24

hs-CRP in Men Over 40: The Inflammation Marker Most Blood Panels Leave Off

Back to Articles

Lab Markers 11 min read Sep 4, 2026

hs-CRP in Men Over 40: The Inflammation Marker Most Blood Panels Leave Off

High sensitivity C-reactive protein is downstream of interleukin-6, which is largely downstream of visceral fat. That chain is why the number moves when body composition moves and stays put when it does not.

Most men over 40 get a lipid panel, a metabolic panel and, if they are paying attention, a hormone panel. Almost none of them get high sensitivity C-reactive protein, which costs a few dollars and predicts cardiovascular events in people whose cholesterol looks fine. hs-CRP is not a disease and it is not a diagnosis. It is a summary number for how much interleukin-6 the body is producing, and in a middle aged man most of that interleukin-6 comes from visceral fat, poor sleep, untreated gum disease and untreated sleep apnea. This article covers what the risk bands actually mean, why a single reading is close to worthless, what the canakinumab and colchicine trials proved about whether inflammation causes events or merely marks them, and what realistically moves the number over twelve weeks.

High sensitivity C-reactive protein, written hs-CRP, is a blood test that measures a protein made by the liver in response to inflammatory signalling. The high sensitivity part refers to the assay, not to a different molecule. A standard CRP test is built to detect the large values seen in acute infection and starts to lose resolution below about 3 to 5 milligrams per litre. The hs-CRP assay reads reliably down to around 0.1 to 0.3 milligrams per litre, which is the range where the cardiovascular signal in otherwise healthy men lives.

The reason this test matters to a man over 40 is that it captures risk that a lipid panel misses. In the Physicians' Health Study and later in the Women's Health Study, C-reactive protein predicted future myocardial infarction and stroke independently of LDL cholesterol, meaning men with unremarkable cholesterol and elevated hs-CRP carried measurably more risk than men with the same cholesterol and a low value. That finding is now thirty years old and hs-CRP is still absent from most routine panels.

Under 1.0

Low Risk Band

milligrams per litre, per the AHA and CDC 2003 statement

Over 3.0

High Risk Band

with 1.0 to 3.0 classified as average risk

Over 10

Retest, Do Not Interpret

suggests acute inflammation, repeat in two weeks

2 draws

Needed For A Usable Value

two weeks apart, averaged, because variability is high

15%

Event Reduction In CANTOS

from an IL-1 beta antibody that did not touch cholesterol

0.13 mg/L

CRP Fall Per Kilogram Lost

pooled estimate across weight loss studies

What is hs-CRP actually measuring?

hs-CRP measures the output of a signalling chain rather than inflammation itself. Cells under stress release interleukin-6, interleukin-6 travels to the liver, and hepatocytes respond by producing C-reactive protein. The value on the report is therefore a downstream readout of how much interleukin-6 the body has been generating over roughly the preceding days. It says nothing about where that signal originated, which is both the strength of the test and its main limitation.

In a man over 40 with no acute illness, the largest single contributor to that interleukin-6 output is usually visceral adipose tissue. Fat around the organs behaves as an endocrine tissue and secretes interleukin-6 and tumour necrosis factor alpha continuously, and estimates from arteriovenous sampling studies attribute a substantial share of circulating interleukin-6 to adipose tissue. This is why hs-CRP tracks waist circumference more tightly than it tracks body weight, and why a lean man with a large abdomen can post a higher value than a heavier man carrying the same mass on his legs.

How A Number On A Blood Report Gets Generated

Source

Tissue Under Load

Visceral fat, periodontal infection, a fragmented sleep pattern, a smoking habit or an untreated sleep apnea all generate a continuous low grade inflammatory signal rather than an acute one

→

↓

Signal

Interleukin-6 Released

Interleukin-6 is the messenger cytokine that carries the signal into circulation, and it has a short half life measured in hours, which makes it impractical to measure directly in routine practice

→

↓

Amplifier

The Liver Responds

Hepatocytes read the interleukin-6 signal and produce C-reactive protein as an acute phase reactant, amplifying a small cytokine change into a protein concentration that a cheap assay can detect

→

↓

Readout

hs-CRP On The Panel

C-reactive protein has a half life of roughly 19 hours and is stable in stored samples, which is why it became the practical marker while interleukin-6 stayed a research measurement

→

↓

Caveat

The Source Is Invisible

The number reports the size of the signal and not its origin, so an elevated value is a prompt to look for a cause and never a diagnosis on its own

What hs-CRP number should a man over 40 want?

Below 1.0 milligrams per litre is the low risk band, 1.0 to 3.0 is average risk and above 3.0 is high risk. Those cut points come from a 2003 joint statement by the American Heart Association and the Centers for Disease Control and Prevention, and they have held up in subsequent cohorts. A value above 10 milligrams per litre sits outside the risk stratification scheme entirely and points toward an acute process such as an infection, a recent injury or a flare of an inflammatory condition, in which case the correct action is to repeat the test in two weeks rather than to interpret it.

A single hs-CRP draw should not be trusted on its own. Within-person variability is high enough that the same man can move between bands on consecutive draws without anything meaningful having changed, which is why the AHA and CDC statement recommends two measurements taken about two weeks apart and averaged. A hard training session in the previous 48 hours, a cold, a dental cleaning or a night of very poor sleep can all lift the number. Men who test once, see 4.2, and start rearranging their lives are usually reacting to noise.

Typical hs-CRP Values Across Different States In Middle Aged Men

How To Read An hs-CRP Result

Result	Classification	What it means in practice	Reasonable next step
Under 1.0 mg/L	Low risk band	The inflammatory contribution to cardiovascular risk is small, and risk assessment rests on lipids, blood pressure, glucose and family history	Repeat every one to two years alongside the rest of an annual panel
1.0 to 3.0 mg/L	Average risk band	The most common band for men over 40 and the least informative one, since it neither reassures nor alarms	Confirm with a second draw and interpret alongside waist circumference, apoB and fasting insulin rather than alone
Above 3.0 mg/L on two draws	High risk band	A persistent low grade inflammatory load that predicts events independently of cholesterol, most often driven by adiposity or an unrecognised chronic source	Look actively for a cause, covering visceral fat, dental health, sleep apnea, smoking and any untreated chronic condition, with a physician
Above 10 mg/L	Outside the risk scheme	Consistent with an acute inflammatory process rather than a chronic baseline, and the risk bands do not apply	Repeat in two weeks once any acute illness has resolved, and take a persistently high value to a physician
Rising across serial draws	Trend rather than a band	A trend in the same man measured under the same conditions carries more information than any single value compared against a population cut point	Standardise the conditions, avoid drawing within 48 hours of hard training or illness, and use the same laboratory

One Number Above 10 Is Not A Finding

The single most common error with this test is treating a value above 10 milligrams per litre as a severe version of a value of 4. It is not on the same scale. Readings in that range generally reflect an acute phase response to infection, injury, recent surgery or an inflammatory flare, and the cardiovascular risk bands were never validated there. The AHA and CDC guidance is explicit that such results should prompt a repeat test after the acute process has resolved rather than an interpretation. A value that stays above 10 across repeated draws is a reason to see a physician about the underlying cause and is not something to address with diet changes and a supplement.

Does lowering inflammation actually reduce risk, or is hs-CRP just a marker?

The evidence that inflammation is causal rather than merely correlated comes from CANTOS, a trial that lowered inflammation without touching cholesterol. Ridker and colleagues, publishing in the New England Journal of Medicine in 2017, randomized 10,061 patients with a prior myocardial infarction and an hs-CRP of at least 2 milligrams per litre to canakinumab, a monoclonal antibody against interleukin-1 beta, or placebo. The 150 milligram dose reduced major adverse cardiovascular events by about 15 percent with no change in LDL cholesterol. That result is the cleanest available demonstration that the inflammatory pathway itself contributes to events.

CANTOS also came with a cost that is usually left out of the summary. Canakinumab increased fatal infections relative to placebo, and the drug was never approved for cardiovascular prevention. The companion result is CIRT, published by Ridker and colleagues in 2019, which tested low dose methotrexate in a similar population and failed outright. Methotrexate did not lower interleukin-6, did not lower C-reactive protein and did not reduce events. Read together, the two trials say something specific: reducing the interleukin-1 to interleukin-6 to CRP axis appears to help, and reducing inflammation by some other mechanism does not automatically do anything.

The Trials That Defined What hs-CRP Means

Trial	Population and design	Intervention	Result
JUPITER, Ridker and colleagues, New England Journal of Medicine, 2008	17,802 adults with LDL cholesterol under 130 mg/dL and hs-CRP of 2.0 mg/L or higher, randomized and placebo controlled, stopped early at a median of 1.9 years	Rosuvastatin 20 mg daily	A 44 percent reduction in the primary composite endpoint in people who would not have qualified for a statin on cholesterol alone, establishing hs-CRP as a way of selecting who benefits
CANTOS, Ridker and colleagues, New England Journal of Medicine, 2017	10,061 patients with prior myocardial infarction and hs-CRP of 2.0 mg/L or higher, randomized and placebo controlled	Canakinumab, an interleukin-1 beta monoclonal antibody, at three dose levels	Roughly a 15 percent reduction in major adverse cardiovascular events at the 150 mg dose with no change in LDL cholesterol, alongside a small excess of fatal infection
CIRT, Ridker and colleagues, New England Journal of Medicine, 2019	4,786 patients with prior myocardial infarction and either type 2 diabetes or metabolic syndrome, randomized and placebo controlled	Low dose methotrexate, 15 to 20 mg weekly	No reduction in interleukin-6, C-reactive protein or cardiovascular events, showing that lowering inflammation by an unrelated mechanism is not sufficient
COLCOT, Tardif and colleagues, New England Journal of Medicine, 2019	4,745 patients randomized within 30 days of a myocardial infarction	Colchicine 0.5 mg daily	A 23 percent reduction in the primary ischaemic composite endpoint relative to placebo
LoDoCo2, Nidorf and colleagues, New England Journal of Medicine, 2020	5,522 patients with chronic coronary disease, randomized and placebo controlled over a median of 28.6 months	Colchicine 0.5 mg daily	A 31 percent reduction in the primary cardiovascular composite endpoint, supporting the inflammatory pathway with an inexpensive generic drug

None of these trials tested an intervention that a man buys for himself. Canakinumab, methotrexate and colchicine are prescription drugs studied in people who had already had a heart attack or had established coronary disease, and every one of those decisions belongs to a physician working from a full clinical picture. What the trials establish for a healthy man over 40 is narrower and still useful. The inflammatory axis that hs-CRP reports on is not a bystander, so a persistently elevated value is worth understanding rather than filing away.

What raises hs-CRP in a man over 40?

Visceral adiposity is the dominant driver in most men, and the remaining contributors are individually smaller but frequently overlooked. Periodontal disease is a genuine chronic infection with a measurable systemic signal, and treating it lowers C-reactive protein in randomized studies. Untreated obstructive sleep apnea raises the number through intermittent hypoxia and sympathetic activation, which matters because sleep apnea is both common and underdiagnosed in men over 40 with a thick neck and a large waist. Smoking raises it directly. Chronic psychological stress and short sleep raise it modestly.

Where The Inflammatory Signal Typically Comes From In A Man Over 40 With An Elevated Value

Visceral and central adipose tissue
Insulin resistance and glycaemic load, partly overlapping with adiposity
Untreated sleep apnea and chronic short sleep
Periodontal disease and other low grade chronic infection
Smoking, alcohol and other exposures
Genetic setpoint and unexplained variation

This breakdown is an illustration of relative contribution rather than a measured partition from any single study, and the categories overlap heavily in real men, since central adiposity, insulin resistance and sleep apnea travel together. The practical value of the picture is the order. A man who adds a curcumin capsule while carrying 110 centimetres of waist and an undiagnosed apnea is working on the small slice and ignoring the large one.

How is hs-CRP connected to testosterone?

Low total testosterone and elevated hs-CRP travel together in observational data, and the direction of that relationship is genuinely unsettled. Cross sectional studies in middle aged and older men consistently find an inverse association between testosterone and inflammatory markers including C-reactive protein and interleukin-6. The obvious confounder is visceral fat, which independently lowers testosterone through increased aromatase activity and raises inflammatory signalling, so a shared cause can produce the association without either variable acting on the other.

Interventional data on whether testosterone therapy lowers C-reactive protein is mixed and does not support treating an inflammatory marker with a hormone. Some trials report reductions in inflammatory markers with testosterone treatment in hypogonadal men, others report no change, and the studies differ in population, formulation, duration and baseline adiposity. The reasonable position for a man reading his own labs is that a low testosterone reading and a high hs-CRP reading in the same panel are more likely to share a driver than to cause one another, and the shared driver is usually visible around his waist.

What actually lowers hs-CRP?

Fat loss is the intervention with the most consistent effect, at roughly 0.13 milligrams per litre of C-reactive protein reduction per kilogram lost in pooled analyses of weight loss studies. For a man dropping 10 kilograms that predicts something in the region of a 1.3 milligrams per litre fall, which is enough to move a typical man from the high risk band into the average one. Exercise lowers the number too, but meta-analyses suggest most of that effect runs through fat loss rather than through training independently, which means a training program that does not change body composition often does not change hs-CRP much either.

Losing visceral fat

The largest and most reliable lever, with pooled estimates near 0.13 mg/L per kilogram of weight lost. Waist circumference tracks the effect better than scale weight, so a man whose waist is falling is usually moving the marker even when the scale is slow

Treating periodontal disease

Randomized studies of periodontal treatment report measurable reductions in C-reactive protein. This is the cheapest overlooked item on the list and a dental appointment is the entire intervention

Diagnosing and treating sleep apnea

Untreated obstructive sleep apnea raises inflammatory markers, and it is common in men over 40 with central adiposity. A home sleep study answers the question that no supplement will

Stopping smoking

Smoking raises C-reactive protein directly and the value falls after cessation. Nothing else on this list competes with it for a man who smokes

Omega-3 intake

Marine omega-3 intake is associated with lower inflammatory markers, though trial results on hard endpoints have been inconsistent across formulations and doses, and the effect on hs-CRP itself is modest compared with fat loss

Statins and colchicine

Statins lower C-reactive protein alongside LDL, and colchicine lowered events in COLCOT and LoDoCo2. Both are prescription decisions made by a physician in the context of overall cardiovascular risk, not self directed inflammation management

A Twelve Week Structure For Testing And Moving The Number

Weeks 0 to 2: Establish a real baseline

✓Draw hs-CRP twice about two weeks apart and average the two values, because a single reading has enough within-person variability to move a man between risk bands on its own
✓Avoid drawing within 48 hours of a hard training session, a dental cleaning, a vaccination or any acute illness, since all of these lift the number temporarily
✓Record waist circumference at the navel with a tape measure, since waist tracks the inflammatory signal more closely than body weight does
✓Draw fasting insulin, HbA1c, apoB and a full hormone panel at the same time, because hs-CRP interpreted in isolation tells you very little

Weeks 2 to 4: Look for a source before assuming it is fat

✓Book a dental examination if you have not had one in the past year, since periodontal disease is a chronic infection with a systemic inflammatory signal and is silent in most men who have it
✓Take a home sleep study seriously if you snore, wake unrefreshed, or have a collar size above 43 centimetres, as untreated apnea raises inflammatory markers and will not respond to diet
✓List every medication and supplement, since some raise inflammatory markers and some suppress them, which can make a value uninterpretable
✓Take a value that stayed above 10 mg/L on both draws to a physician rather than starting a self directed program

Weeks 4 to 10: Work the largest lever

✓Aim for a rate of fat loss you can hold, roughly 0.5 to 0.75 percent of body weight per week, since the pooled data ties the CRP reduction to the kilograms lost rather than to the method used
✓Keep resistance training in the program to protect lean mass during the deficit, and treat cardiovascular work as support for the deficit rather than as an independent inflammation treatment
✓Fix sleep duration before adding anything to the stack, because short and fragmented sleep raises inflammatory signalling and undermines the fat loss at the same time
✓Change one large variable at a time so that a change in the number at week 12 can be attributed to something

Weeks 10 to 12: Retest under matched conditions

✓Repeat hs-CRP at the same laboratory, at the same time of day, and again as two draws two weeks apart rather than one
✓Compare the new average against the old average and against the change in waist circumference, since those two numbers should move together if the mechanism is what you think it is
✓Treat a value that has not moved despite genuine fat loss as a prompt to look for an unidentified source rather than to escalate supplements
✓Take the whole picture, meaning hs-CRP alongside apoB, blood pressure, glucose and family history, to a physician for an actual risk assessment

hs-CRP Falling Alongside Sustained Fat Loss Across A Twelve Week Window

This curve illustrates the shape and approximate magnitude implied by the pooled weight loss estimate for a man starting at 3.6 milligrams per litre and losing roughly 10 kilograms, rather than measured data from a single trial. Real serial measurements in one man are far noisier than this line, and the value will bounce upward after a hard training block or a cold. The feature worth taking from it is that the change is gradual and tied to the kilograms, which is why a four week experiment answers nothing.

So is hs-CRP worth adding to a panel?

hs-CRP is worth adding for a man over 40 whose cardiovascular risk sits in the ambiguous middle, and it is close to pointless for a man who will not act on the result. It costs a few dollars as an add-on to a panel he is already drawing, and its main use is reclassification. A man with mediocre cholesterol and an hs-CRP of 0.4 is in a different position from a man with the same cholesterol and a repeated value of 4.5, and JUPITER showed that the second man is the one who benefits most from a treatment decision he would not otherwise have qualified for.

The failure mode is treating the marker as the target. hs-CRP is a readout of a process, and the useful response to an elevated value is to find what is generating the signal rather than to assemble a stack of anti-inflammatory supplements aimed at the number itself. In the majority of men over 40 that search ends at visceral fat, an untreated sleep disorder or a dental problem, and all three of those have real interventions attached. The number is a pointer, and its value comes entirely from where it points.

Medical Disclaimer

This article is for educational purposes only and is not medical advice. Nothing here diagnoses, treats, cures or prevents any disease or condition, including cardiovascular disease, obstructive sleep apnea, periodontal disease, metabolic syndrome or hypogonadism. Canakinumab, methotrexate, colchicine and statins are prescription medications discussed here only in the context of what published randomized trials measured, and none of them should be sought or used outside the care of a licensed clinician. Blood test interpretation, including hs-CRP, belongs with a physician who has your full history in front of them. Testosterone therapy is a prescription treatment and every decision about it belongs with a licensed clinician working from your bloodwork. The charts in this article are illustrative representations of direction, relative magnitude and physiological pattern rather than measured trial results, and the studies referenced differ in population, intervention, duration and endpoint, so their figures are not directly comparable to one another.